(Q42615391)

3 November 2017

Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines (English)

1 reference

3 November 2017

Victoria A Sharma

1

1 reference

3 November 2017

Elaine Kan

2

1 reference

3 November 2017

Yide Sun

3

1 reference

3 November 2017

Ying Lian

4

1 reference

3 November 2017

Jimna Cisto

5

1 reference

3 November 2017

Verna Frasca

6

1 reference

3 November 2017

Susan Hilt

7

1 reference

3 November 2017

Leonidas Stamatatos

8

1 reference

3 November 2017

John J Donnelly

9

1 reference

3 November 2017

Jeffrey B Ulmer

10

1 reference

3 November 2017

Susan W Barnett

11

1 reference

3 November 2017

Indresh K Srivastava

12

1 reference

3 November 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

3 November 2017

1 reference

3 November 2017

352

1 reference

3 November 2017

1

1 reference

3 November 2017

131-144

1 reference

Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein

3 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces cerevisiae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

A vaccine for HIV type 1: the antibody perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Structure of an unliganded simian immunodeficiency virus gp120 core

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Entropy calculation of HIV-1 Env gp120, its receptor CD4, and their complex: an analysis of configurational entropy changes upon complexation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Viral persistence: HIV's strategies of immune system evasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Human immunodeficiency virus: refolding the envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Energetics of the HIV gp120-CD4 binding reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Characterization of a neutralization-escape variant of SHIVKU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Glycosylation and stability of mature HIV envelope glycoprotein conformation under various conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

HIV-1 antibody--debris or virion?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

A role for carbohydrates in immune evasion in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

The CD4 antigen: physiological ligand and HIV receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Epitope exposure on functional, oligomeric HIV-1 gp41 molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Protein−Protein Interactions: Interface Structure, Binding Thermodynamics, and Mutational Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Epitopes recognized by HIV-SF2 nef-specific CD4+ T-cell clones generated from HIV-1-uninfected donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

7 January 2021

Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

7 January 2021

Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

7 January 2021

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

7 January 2021

Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

7 January 2021

An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

7 January 2021

Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

7 January 2021

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.04.030

7 January 2021

10.1016/J.VIROL.2006.04.030

Identifiers

DOI

1 reference

3 November 2017

1 reference